Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Delta-Tocotrienol for Preventing Progression to Cancer in Patients with Intraductal Papillary Mucinous Neoplasms

Trial Status: administratively complete

This phase II trial tests how well delta-tocotrienol works in preventing pancreatic cysts from growing and developing into cancer. Intraductal papillary mucinous neoplasms (IPMNs) are cystic tumors of the pancreas. Currently, there is a lack of research that examines drugs for chemoprevention of patients with IPMN undergoing active surveillance, underscoring the need to identify and test new drugs in this target population. Delta-tocotrienol is a natural vitamin E compound that has been consumed by humans as a dietary supplement. Delta-tocotrienol has been shown to be effective in killing human pancreatic tumor cells. Delta-tocotrienol may be effective in preventing pancreatic tumors from growing and developing into cancer in patients with IPMNs.